About: Big pharma

OpinionPromoted content
Health 12-12-2017

Drugs incentives have saved lives in Europe

Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.

Health 10-10-2017

Pharma boss: Targeting drugs won’t make healthcare systems more sustainable

“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.

Brexit 26-04-2017

Drugs firms call for phased transition of regulation after Brexit

Pharmaceutical companies called on Thursday (27 April) for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.

Health 29-09-2016

Fake drugs cost EU billions of euros, its health and its jobs

Counterfeit drugs are not only hazardous to health, they cost people their jobs too, a new EU study has revealed. But Germans in particular are willing to take risks. EURACTIV's partner Der Tagesspiegel reports.

Trade & Society 23-09-2016

Don’t be fooled by CETA: It’s a wolf in sheep’s clothing

In his State of the Union speech, Jean-Claude Juncker called the Canada-EU trade agreement the most progressive trade agreement the EU has ever negotiated. It actually poses a genuine threat to the health sector, argues Emma Woodford.

Health 07-09-2015

EU needs compulsory transparency register to rein in Big Pharma lobbying

Big Pharma is out-gunning its civil society and non-profit rivals in terms of lobbying, access, and influence at the EU institutions, write David Lundy and Rachel Tansey.